Abstract Purpose: Variants at chromosomal loci 8q24 and 17q are established risk factors for prostate cancer. Many studies have confirmed the findings for risk, but few have examined aggressiveness and other clinical variables in detail. Additionally, Gleason score is typically used as a surrogate for the primary end point of prostate cancer mortality.We investigated whether the 8q24 and 17q risk variants are associated with clinical variables as well as prostate cancer mortality. Experimental Design: In the Physicians' Health Study (1,347 cases and 1,462 controls), the Dana-Farber Harvard Cancer Center Specialized Program of Research Excellence (Gelb Center; 3,714 cases), and the Fred Hutchinson Cancer Research Center King County Case-Control Studies (1,308 cases and 1,266 controls), we examined eight previously identified 8q24 and 17q risk variants for association with prostate cancer mortality in men of European ancestry.We considered associations with other surrogate markers of prostate cancer aggressiveness, such as Gleason score, pathologic stage, prostate-specific antigen at diagnosis, and age at diagnosis. Results: Six of the eight variants were confirmed as prostate cancer risk factors. Several variants were nominally associated with age at diagnosis; when totaling all alleles for single nucleotide polymorphisms significantly associated with risk, each additional allele decreased age at diagnosis by an average of 6 months in the Physicians' Health Study (P = 0.0005) and 4 months in the Dana-Farber Harvard Cancer Center Specialized Program of Research Excellence (Gelb Center) cohort (P = 0.0016). However, there were no statistically significant associations with prostate cancer mortality. Conclusions: Our results suggest that the 8q24 and 17q prostate cancer risk variants may influence age at diagnosis but not disease aggressiveness.
Chromosomal loci 8q24 and 17q have emerged recently as bona fide prostate cancer risk loci (1 -17) . Fine mapping (18) and additional genome scans (4, 5) have identified three 8q24 regions containing variants independently associated with risk (hg18 build 36; region 1: 128.54-128.62 Mb; region 2: 128.12-128.28; region 3: 128.47-128.54; ref. 19) . Notably, none of the variants in regions 1 to 3 lie in or near known coding regions. A single nucleotide polymorphism (SNP) outside these regions was recently identified as a novel risk factor in AfricanAmericans (20) . This SNP lies in an intron of the non-SMC element 2 gene. The risk SNPs identified on chromosome 17q lie in two regions: one in a noncoding region at 17q24.3 and the other in the second intron of TCF2/HNF1b at 17q12 (3) .
Although variants in these regions unambiguously confer risk of developing disease, their association with mortality or with other important prostate cancer traits is unknown. Most men with clinically localized prostate cancer are treated as if they have lethal disease because of the limited ability to predict outcome. However, most men with localized prostate cancer have indolent disease that would not be lethal even in the absence of early aggressive therapy (21, 22) . Because aggressive therapy is not without associated morbidity and costs, it is imperative to find markers that can distinguish indolent from fatal disease at diagnosis.
In previous studies, some of the 8q24 and 17q alleles have shown modest associations with prostate cancer clinical parameters, such as Gleason score (8, 16) or age at diagnosis (1, 3, 4, 6, 17, 18) , whereas other studies failed to show an association with aggressive characteristics (1, 2, 5 -7, 9, 23) or age at diagnosis (5, 7, 11, 23) . Additionally, the majority of work to date has focused on one of the first 8q24 SNPs detected, rs1447295; no single study has yet examined multiple 8q24 and 17q risk variants in relation to prostate cancer mortality.
Mortality is inarguably the most important prostate cancer end point. As substantial longitudinal follow-up is required to capture this information, many studies define ''aggressive'' cancers as those with high Gleason score. Gleason score is a strong predictor of mortality; however, the positive predictive value for mortality of a high Gleason score (z7) is only 29% (24) and therefore far from optimal. Both prostate cancer mortality and Gleason score likely have genetic determinants. A recent study showing concordance of survival among family members with prostate cancer suggests that prostate cancer prognosis may have a hereditary component (25) . Several linkage scans have identified regions of the genome associated with Gleason score (26 -28) . However, there is a trade-off when choosing which of these outcomes to investigate-studies of Gleason score are likely to have more statistical power because of the larger sample size, but the end point of mortality will provide more useful information. In the largest study of its kind, the present investigation evaluated the association of genetic risk variants with mortality (n = 491 prostate cancer deaths) across three cohorts.
We evaluated six 8q24 and two 17q risk variants in participants from three large, well-annotated studies: the Physicians' Health Study (PHS), the Dana-Farber Harvard Cancer Center Specialized Program of Research Excellence (SPORE; Gelb Center) cohort, and the Fred Hutchinson Cancer Research Center (FHCRC) King County Case-Control Studies. We tested for associations between these eight SNPs and several clinicopathologic traits [Gleason score, pathologic stage at radical prostatectomy, age at diagnosis, and prostate-specific antigen (PSA) at diagnosis] and prostate cancer mortality.
Materials and Methods

Study populations
This study received Institutional Review Board approval at each participating institution.
Physicians' Health Study. The PHS began as a randomized, doubleblind trial of aspirin and h-carotene in the prevention of cardiovascular disease and cancer among 22,071 healthy U.S. physicians. Written consent was obtained from each participant and the investigation was approved by the Human Subjects Committee at Brigham and Women's Hospital. Men were excluded at baseline if they had any serious medical conditions, including all cancers (except nonmelanoma skin cancer). Blood samples were collected from 68% of the physicians in 1982 to 1984 as described previously (29) . Participants are followed through annual questionnaires to collect data on diet, health and lifestyle behaviors, and medical history, and biannually through postcards to ascertain health end points, including prostate cancer. All self-reported prostate cancer cases are verified through medical record and pathology review. Through this systematic medical record review, we also abstract data on PSA at diagnosis, tumor stage, and Gleason score. Cause of death is determined by review of death certificates, medical records, and information from the family by a panel of three physicians. There is high follow-up for both cancer incidence (96%) and mortality (98%). Metastases are reported on follow-up questionnaires sent to all men living with prostate cancer. We used a nested case-control study, with controls selected by risk-set sampling and matched on age at baseline (F1 y and, for older cases, within 5 y), smoking status (never, former, current), and follow-up time. For the current study, we restricted participants to self-reported Caucasians. Cases (1,347) and controls (1,462) were included from PHS for the matched case-control analysis; controls that were later diagnosed with prostate cancer were included in the case-only analyses. During follow-up through March 1, 2008, 187 men died of prostate cancer. In this cohort, follow-up for vital status was more than 99% complete.
Dana-Farber Harvard Cancer Center SPORE (Gelb Center). DanaFarber Harvard Cancer Center SPORE (Gelb Center) is a case series of prostate cancer patients diagnosed between 1976 and 2007. A detailed description of this study has been published previously (30) . The study includes detailed clinical information from multiple sources, including medical records and patient registration, and a blood sample collected after diagnosis. Follow-up of the participants occurs at clinic visits to the Dana-Farber Cancer Institute and by searching the National Death Index. Because cause of death is not always available or known, if an individual was known to have metastases before death they were assumed to have died from prostate cancer. Long-term survivors were defined as men who survived at least 10 y beyond their prostate cancer diagnosis; these cases were additionally restricted to those who had a follow-up visit at Dana-Farber at least 10 y after diagnosis and were free of metastases at that time. Individuals who reported their ethnicity as non-Caucasian or were missing information on ethnicity or age at diagnosis were excluded.
FHCRC King County Case-Control Studies. The study population consists of participants from two population-based case-control studies in residents of King County, Washington (study I and study II), which have been described previously (31, 32) . Incident cases diagnosed between 1993 (study I) and 2002 and 2005 (study II) with histologically confirmed prostate cancer were ascertained from the Seattle-Puget Sound SEER cancer registry. Of the 2,244 eligible prostate cancer patients identified, 1,754 (78.2%) were interviewed. Controls were male residents of King County, Washington without a selfreported history of prostate cancer. They were identified using one-step random digit dialing and recruited evenly throughout both ascertainment periods. Controls were frequency matched to case patients by 5-y age groups. Of the 2,448 men identified who met the eligibility criteria, 1,645 (67.2%) completed a study interview. Subjects in both studies completed in-person interviews using a questionnaire that collected information on social and demographic factors, family structure, cancer
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Many prostate cancer cases diagnosed by prostatespecific antigen screening will have an indolent course of disease even in the absence of therapy. However, one of the key questions in prostate cancer research is how to predict at diagnosis which patients have lethal cancer and which patients have indolent cancer. Identifying genetic determinants of prostate cancer aggressiveness would have clinical utility. Genetic studies primarily have focused on surrogates of prostate cancer aggressiveness, such as Gleason grade. In this study, we investigated the association between genetic markers and prostate cancer mortality, the primary end point of interest. The genetic markers examined are known prostate cancer risk polymorphisms at chromosomes 8q24 and 17q; determining whether these markers predict prostate cancer mortality or other clinical covariates is required for evaluating if and how these markers will inform clinical decision making.
history, and medical history. Clinical information on cases, including Gleason score, stage of disease, serum PSA level at diagnosis, and primary treatment, was obtained from the cancer registry. For this analysis, only Caucasian cases (n = 1,308) and controls (n = 1,266) were included. Cases from both studies are under long-term surveillance with ascertainment of vital status and underlying cause of death. The patient file is linked to the SEER cancer registry, and for each deceased case, a death certificate is requested to confirm the underlying cause of death. Long-term survivors had not progressed according to self-administered survey and medical record review. The date of last follow-up for vital status for this analysis was November 1, 2007, with an average length of follow-up of 7.6 y (11.9 y for study I and 4.0 y for study II). All study subjects signed informed consent before participation, and the studies were approved by the FHCRC Institutional Review Board.
DNA, SNPs, and genotyping
In all cohorts, DNA was extracted from whole blood. SNPs in the 8q24 and 17q regions associated with prostate cancer incidence were genotyped. These SNPs include rs13254738, rs1447295, rs6983267, rs6983561, rs7000448, and rs7008482 (not in FHCRC) at 8q24 and rs4430796 and rs1859962 at 17q. On the PHS and Gelb Center specimens, genotyping was done with Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry technology (see ref. 33 for reaction details). For quality control, six SNPs were genotyped on a subset of PHS (n = 598) and Gelb Center (n = 772) specimens twice; concordance was >99%. In the FHCRC studies, SNPs were genotyped using the Applied Biosystems SNPlex Genotyping System. Identification of the specific SNP allele was carried out with the Applied Biosystems 3730xl DNA Analyzer with GeneMapper software used for allele assignment. Quality control included genotyping of 140 blind duplicate samples distributed across all genotyping batches, with 100% agreement between duplicates for the SNPs. For PHS and FHCRC, batches genotyped incorporated similar numbers of case and control samples and laboratory personnel were blinded to the case-control status of samples. All SNPs had >94% genotype passing rates.
Statistical analysis
We tested for Hardy-Weinberg proportions in the PHS and FHCRC controls using Pearson's goodness-of-fit test. No SNPs violated HardyWeinberg equilibrium in either the PHS or FHCRC controls (P > 0.01). SNPs that had a minor allele frequency of >10% were analyzed under a codominant model, whereas the less common SNPs were analyzed assuming a dominant inheritance model. P values reported were for trend (1-degree-of-freedom test). We created a variable for total number of risk alleles using only the SNPs that were significantly associated with prostate cancer risk in the PHS and FHCRC combined results.
Prostate cancer incidence. Prostate cancer incidence was investigated only in the PHS and the FHCRC case-control studies, as there are no controls in the Gelb Center. These data were analyzed by unconditional logistic regression, adjusting for the matching factors, to estimate odds ratio (OR) as an approximation of the rate ratio, and 95% confidence intervals (95% CI). The resulting ORs were combined into a summary estimate across the two cohorts using a random-effects model, with cohort as the random effect.
Prostate cancer mortality. To study the extremes of prostate cancer, we selected cases who died of prostate cancer and cases who survived for at least 10 y of follow-up after diagnosis without developing metastases (to represent indolent cases). An analysis comparing these two groups was carried out using unconditional logistic regression, adjusting for age at diagnosis. The resulting ORs were combined across the three cohorts into a summary estimate using a random-effects model.
A survival analysis using the Cox proportional hazards model, adjusting for age at diagnosis, was done in only the PHS and FHCRC studies, where date and cause of death was known for all participants who died. Individuals who died of other causes or were still alive at end of follow-up (2008 in PHS and 2007 in FHCRC) were censored.
Gleason score. We examined the association between SNPs and Gleason score in a case-only analysis using a three-category variable [<7 (referent), 7, and >7] with polytomous logistic regression, adjusting for age at diagnosis. For the men who underwent prostatectomy, Gleason score was preferentially from prostatectomy; for all others, Gleason score from biopsy was used. The resulting ORs were combined into a summary estimate using a random-effects model.
Pathologic stage. Among the cases, we classified men as either having evidence of extraprostatic disease (T3/T4) or localized disease (T2) at prostatectomy. We examined the relationship between each of the SNPs and this binary variable with unconditional logistic regression, adjusted for age at diagnosis. The resulting ORs were combined into a summary estimate using a random-effects model.
Age and PSA at diagnosis. The relationships between the 8q24 and 17q SNPs and age at diagnosis and PSA at diagnosis were analyzed with ANOVA; the analysis of total number of risk alleles was done with linear regression. The FHCRC studies oversampled younger patients and cases in older age groups were randomly selected at diagnosis; thus, the age distribution is a result of the sampling scheme. Individuals who were known to be clinical stage T4 at diagnosis were excluded from the PSA analysis. PSA values were log transformed and this analysis was adjusted for age at diagnosis.
Statistical significance was declared when the two-sided P value was <0.05. Analyses were done using Statistical Analysis System v.9.1 statistical software.
Results
Selected clinical characteristics of the PHS, the Gelb Center, and the FHCRC studies are described in Table 1 . These studies and the participants differ: PHS being a prospective cohort study, the Gelb Center a referral hospital-based case series, and FHCRC two population-based case-control studies. The mean age of diagnosis is 70.5 in the PHS compared with 62 in the Gelb Center and 59.9 in FHCRC. Whereas most tumors are Gleason 7 or less in all three studies, a large proportion of the Gelb Center patients is Gleason score 8 to 10 (21.5%). Many PHS cases were diagnosed before 1992 in the pre-PSA era (28%). Genotype frequencies for all eight SNPs are similar to those reported in previous studies for both cases and controls (Supplementary Table S1 ).
Prostate cancer incidence. Results for the association of 8q24 variants with prostate cancer incidence in the FHCRC studies were previously published (14) . In the PHS and FHCRC combined case-control analyses, four of the variants in the 8q24 region were significantly associated with risk of prostate cancer (rs13254738, rs6983561, rs6983267, and rs1447295; Supplementary Table S2 ). Of note, the two variants that were not significantly associated with risk in our study have been reported as significant risk factors only in non-White populations. We found that both 17q risk SNPs, rs4430796 and rs1859962, were also significantly associated with prostate cancer (Supplementary Table S2 ). The ORs for the homozygote risk alleles in the combined analysis ranged from 1.28 (95% CI, 1.06-1.54) for rs13254738 to 1.60 (95% CI, 1.37-1.88) for rs4430796. We created a variable for the total number of alleles by adding up the alleles for all SNPs significantly associated with risk (rs13254738, rs6983561, rs6983267, rs1447295, rs4430796, and rs1859962; range, 0-9); with each additional risk allele, the risk of prostate cancer increased 19% (P < 0.0001) in PHS and 23% (P < 0.0001) in the FHCRC studies.
Prostate cancer mortality. We examined the association of these variants with prostate cancer mortality by comparing prostate cancer deaths to long-term survivors (alive z10 years after diagnosis). rs1859962 was associated with prostate cancer mortality in the Gelb Center cohort only; having the risk allele was associated with an increased risk of mortality of f70% (Table 2) . In all cohorts, the total number of risk alleles was not associated with mortality, with P values for trend ranging from 0.23 to 0.99 (results not shown). When results from the three studies were combined, none of the SNPs were significantly associated with prostate cancer mortality ( Table 2) . We also did a survival analysis among all the cases in the PHS and FHCRC studies; again, no significant associations with mortality were observed (data not shown).
Gleason score and pathologic stage. Using polytomous logistic regression, cases with Gleason score 7 (total n = 2,151; Supplementary Table S3) and Gleason score 8 to 10 (total n = 1,063; Table 3 ) were compared with the referent of Gleason score 2 to 6 (total n = 2,822). In the combined summary estimate, the rs6983267 heterozygotes had a lower risk of Gleason 8 to 10 cancer (OR, 0.82; 95% CI, 0.67-0.99); however, no association was observed for the GG homozygote (Table 3) .
Carriers of the rs6983267 risk allele had a decreased risk of pathologic stage T3/T4 cancer in the Gelb Center (Table 4) , but this did not persist when the results from the three studies were combined. In the combined results, the rs7008482 TT homozygote was associated with a decreased risk of stage T3/T4 cancer (P = 0.01), whereas the GT heterozygote of rs1859962, but not the homozygote, was associated with an increased risk of T3/T4 cancer (P = 0.03).
Age and PSA at diagnosis. Several variants were significantly associated with age at diagnosis in the Gelb Center study (rs13254738, rs6983267, rs4430796, and rs1859962; Table 5 ). The total number of risk alleles was strongly associated with a younger age of diagnosis in both the PHS and Gelb Center; with each additional risk allele, the age at diagnosis decreased by 6 months (P = 0.0005) or 4 months (P = 0.0016), respectively (Fig. 1) . However, number of risk alleles was not associated with age at diagnosis in the FHCRC studies (P = 0.26).
Although rs6983267 was significantly associated with PSA level at diagnosis in the FHCRC studies (P = 0.04), no other associations with PSA were observed (Supplementary Table S4 ).
Discussion
This study comprehensively examined the association of known prostate cancer risk variants at 8q24 and 17q with prostate cancer mortality and other clinical variables. Additionally, this study replicated the findings that polymorphisms in these regions are associated with prostate cancer risk. Six of the eight previously reported risk variants that we tested were significantly associated with prostate cancer incidence in a large case-control study nested in the PHS and in the FHCRC Case-Control Studies. The SNPs that were not significantly associated with risk were previously associated only in nonWhite populations; we did not attempt to replicate these findings as our analyses were only powered for populations of European ancestry.
Although prostate cancer is very common, a minority of those diagnosed will die from their disease. The ability to predict a patient's course of disease at diagnosis would be of tremendous clinical utility. In our study populations, we examined the association of the 8q24 and 17q variants with the primary end point of prostate cancer mortality, the most important clinical outcome. None of the SNPs were significantly associated with mortality in our combined analysis. This combined analysis is the largest of its kind (493 prostate cancer deaths and 1,268 long-term survivors). It takes years of follow-up to identify lethal prostate cancer cases, so many studies use Gleason score as a surrogate for prostate cancer mortality. Gleason score is frequently used as a marker of aggressive disease because it is readily obtainable. However, there are significant limitations in using Gleason score as a predictor of lethal disease, such as interobserver variability, grading changes over time (34, 35) , and the relatively low positive predictive value for death at higher Gleason scores (24) . There may be some misclassification when using long-term survivors to represent ''indolent'' cancers (i.e., some will still die of prostate cancer or some may have only survived due to aggressive therapy). However, we attempted to limit the first concern by selecting only patients who survived a minimum of 10 years after diagnosis. The second issue is present in any study of survival in a treated population; if we assume that this misclassification is nondifferential, we could be missing small effects. We believe, however, that the majority of the long-term survivors would have survived even in the absence of treatment. As the results of the Swedish randomized trial of prostatectomy versus watchful waiting suggest, the number needed to treat to save the life of one man is 19 (36) .
In this study, one marker, rs6983267, was significantly associated with Gleason score and pathologic stage (in the Gelb Center only); this variant was previously shown to be more strongly associated with aggressive cancer (15) . Two other markers, rs7008482 and rs1859962, were associated with pathologic stage but not with Gleason score. Because these variants were not associated with mortality, it is possible that they are truly associated with these clinical traits, but due to treatment and the resulting misclassification, we did not observe associations with mortality. However, given the large number of tests done and the moderate level of significance, one must consider that these results could be due to chance.
Several markers were associated with age at diagnosis in the Gelb Center patients. When we examined total number of risk alleles (adding together all alleles significant for risk), we observed a strong association with age at diagnosis in both the PHS and Gelb Center studies. It is of note that, as one might expect for a genetic disease, men with more risk alleles were more likely to develop cancer at a younger age. Several studies have suggested an association of these alleles with younger age at diagnosis (3, 4, 12, 15, 18) ; however, most dichotomize age and few have looked at the number of risk alleles combined. There was no significant association with age at diagnosis in the FHCRC studies; this may be due to the sampling scheme that selected participants with a younger age of diagnosis (<65), and therefore, there is less variability, making it more difficult to detect a significant trend. Additionally, these cases were all diagnosed in the PSA era, which may affect age at diagnosis. When we stratified PHS cases by PSA era, the association between number of risk alleles and age at diagnosis was stronger in the pre-PSA era (diagnosed before 1992) than the PSA era [decrease of 9 months per risk allele (P = 0.0017) versus decrease of 4 months (P = 0.034), respectively]. Although markers in the 8q24 and 17q regions are definitively associated with prostate cancer risk, their public health and clinical utility remains uncertain if they do not affect clinically relevant outcomes, particularly prostate cancer mortality. Given the high proportion of men who develop prostate cancer in their lifetime, it is crucial to determine whose life expectancy will be shortened by this disease. Understanding the genetic basis of lethal disease could enhance clinical decision making; based on our results, the 8q24 and 17q markers do not seem to contribute information to a predictive model for lethal disease in cases of European ancestry.
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